The L1 and L2 capsid proteins encoded by human papillomavirus types 6 and 16 (HPV-6 and HPV-16) have been synthesized in bacteria. Antisera were raised against the HPV-6 L1-and L2-fl-galactosidase fusion proteins and against an HPV-16 L1 C-terminal peptide which was 14 amino acids long. The HPV-16 L1 peptide antibodies have been shown to be highly reactive with the HPV-16 Ll-fl-galactosidase fusion protein but not against the equivalent HPV-6 Ll-fl-galactosidase fusion protein. The effectiveness of these antibodies was compared with commercially available antibovine papillomavirus type 1 (BPV-1) antibodies and the results demonstrated that the anti-BPV-1 antibodies reacted well against HPV-6 Ll-fl-galactosidase but not against HPV-16 Ll-fl-galactosidase. In addition, the L2 portion of the HPV-6 L2-fl-galactosidase fusion protein appeared particularly immunogenic, since antibodies raised against this fusion protein were predominantly reactive with the L2 moiety. The HPV-16 L1 peptide antibodies described here will be preferred reagents for the specific detection of HPV-16 capsid antigens, which may be particularly important in early diagnosis of HPV-16 infection.
INTRODUCTION
Papillomaviruses are found in a number of higher organisms including man, in which over 40 different types have now been identified. Of these many types, most cause only mild if inconvenient lesions of skin and mucosa (zur Hausen, 1977) . Recently however, a small number of these viruses have been shown to be probable aetiological agents in a number of human cancers of which cervical cancer is by far the most prevalent. Over 90~ of cervical cancer biopsies contain human papillomavirus (HPV) DNA of types 16, 18, 31, 33 or 35, of which types 16 and 18 are most common (zur Hausen, 1985) . Cell lines derived from these tumours have been shown to contain HPV DNA (Diirst et al., 1983; Boshart et al., 1984) , RNA (Schwarz et al., 1985; Schneider-Gadicke & Schwarz, 1986 ) and a number of HPV early proteins (Smotkin & Wettstein, 1986; Banks et al., 1987; Androphy et al., 1987) . In contrast, HPV-6 and HPV-11 infections tend to be associated with benign lesions of the genital tract. Hence early identification of the HPV type in an infection is particularly important, and immunologically based assays seem to offer the most convenient means of diagnosis.
To date most studies on HPV capsid antigens in infected tissue have relied upon commercial anti-bovine papillomavirus type 1 (BPV-1) antisera (Dako, Copenhagen, Denmark) raised
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RESULTS
Expression of HPV-6 capsid proteins in E. coli For HPV-6 L1 the XbaI to HindIII fragment containing coding sequence for amino acids 39 to 501 was cloned into the prokaryotic expression vector pUR288 as described in Methods. This resulted in a construct coding for the HPV-6 L10RF linked to the C terminus of the flgalactosidase gene (Fig. 1 a) . Similarly, for HPV-6 L2 a BamHI to XbaI fragment containing coding sequence for amino acids 94 to 460 was cloned into pUR278. This resulted in a construct coding for the HPV-6 L20RF linked to the C terminus of the fl-galactosidase gene (Fig. 1 b) . Upon IPTG induction the HPV-6 Ll-fl-galactosidase fusion protein synthesized had a mol.wt. of about 153K (Fig. 2a, lane 2) , which was somewhat smaller than would have been estimated from the L1 amino acid sequence linked to fl-galactosidase, although it was apparent that there were a number of degradation products. The HPV-6 L2-fl-galactosidase fusion protein had a mol.wt, of about 160K (Fig. 2a, lane 3) , which was similar to that which would be estimated from the L2 amino acid sequence linked to fl-galactosidase. fragment containing coding sequence for amino acids 78 to 473 was cloned into pUR278 as described in Methods. This construct coded for the HPV-16 L 2 0 R F linked to the C terminus of fl-galactosidase ( Fig. 1 e) . Upon I P T G induction the HPV-16 L l-fl-galactosidase fusion protein synthesized had a mol.wt, of about 125K (Fig. 2b , lane 2) which was considerably smaller than would be estimated from the L1 amino acid sequence, suggesting that a large amount of degradation was taking place. The HPV-16 L2-fl-galactosidase fusion protein synthesized had a mol.wt, of about 130K (Fig. 2 b , lane 3) which was again somewhat smaller than the estimate of 160K mol.wt. Both of the HPV-16 fusion proteins appeared to be unstable, thus explaining the low levels of expression. However, as shown below, an HPV-16 Ll-fl-galactosidase fusion protein of the expected size was detectable by Western blotting, although the protein was not visible on a Coomassie Brilliant Blue-stained gel.
Expression of HPV-16 capsid proteins in
Production of antibodies against HPV-16 L1
From the HPV-16 sequence information it was possible to predict the primary structure of an L1 C-terminal peptide. This was chosen since from our previous experience, antibodies to peptides derived from the C terminus of a protein are most likely to react with the native protein.
A peptide was made which was 14 amino acids long and ended eight amino acids from the C terminus of L1 (Fig. 3a) . This was linked to thyroglobulin and used to inoculate mice. The anti-L1 peptide antiserum was then reacted on Western blots with the Ll-fl-galactosidase fusion proteins. Since the Ll-fl-galactosidase fusion protein generated above tended to become degraded, two additional Ll-fl-galactosidase fusion proteins were used. These proteins consisted of the amino-terminal half of HPV-16 L1 (pHX-1 coding for amino acids 1 to 195) and the carboxy-terminal half of HPV-16 L1 (pHX-2 coding for amino acids 196 to 531) and were found to be more stable than the pUR-derived L1 fusion protein. The results obtained are shown in Fig. 3 . Clearly the antiserum to the L1 peptide reacted strongly with two of the HPV-16 Ll-flgalactosidase fusion proteins (Fig. 3 c, lanes 4 and 5) and, as expected, no reaction was observed against the pHX-1 amino-terminal fusion protein (Fig. 3c, lane 3) . No reaction was observed against either fl-galactosidase alone or the HPV-6 Ll-fl-galactosidase fusion protein (Fig. 3c , lanes 1 and 2 respectively). This result confirms the correct translation of the HPV-16 Ll-flgalactosidase fusion protein. The peptide antiserum detected a band of approximately 145K mol.wt. (Fig. 3 c, lane 5) although only a weak Coomassie Brilliant Blue stained band was visible in this position (Fig. 3b, lane 5) . However, we believe that this stained protein represents a background polypeptide, confirming the extensive degree of degradation of this fusion protein.
Production of antibodies against HPV-6 capsid proteins
The HPV-6 L1-and L2-/~-galactosidase fusion proteins were excised from preparative polyacrylamide gels and used to inoculate mice over a number of weeks as described previously (Banks et al., 1987) . The activity of the antibodies was then determined by Western blot analysis of E. coli H4.4 cells expressing the appropriate fusion protein. The results obtained are shown in Fig. 4 . Anti-HPV-6 L1-/~-galactosidase fusion protein antibodies clearly reacted strongly with both fusion proteins (Fig. 4a) reacted with the L2-fl-galactosidase fusion protein and degradation products thereof, but only very weakly with the Ll-fl-galactosidase fusion protein (Fig. 4b, lane 1) . Only a very weak reaction was observed against pUR-fl-galactosidase alone (data not shown), and the strong reaction obtained against the protein of lower mol.wt. (Fig. 4b, lane 2) represented reaction against residual L2 sequences on the degraded L2-fl-galactosidase fusion protein. This result was particularly surprising, since it demonstrated that virtually the entire humoral response in these mice was directed against the L2 portion of the L2-fl-galactosidase fusion protein. The specificity of these antibodies was investigated further by Western blot analysis on E. coli AR120 cells expressing HPV-6 L2 not fused to fl-galactosidase. This construct was generated as described in Methods (Fig. 1 c) , and upon nalidixic acid induction of these cells a 50K mol.wt. protein was induced (Fig. 5a ). When these cells were reacted with anti HPV-6 L2-flgalactosidase fusion protein antibody, a strong reaction was obtained (Fig. 5b) .
Antigenic analysis of the HPV capsid proteins
From the above data it is apparent that the anti-HPV-16 L1 peptide antiserum would be an ideal reagent for differentiating between HPV-6 and HPV-16. However, we were also interested in determining how they compared with commercially available antisera to papillomavirus eapsid proteins. Hence a series of Western blots were done with the papillomavirus capsid proteins using antisera to BPV capsid antigens (Jenson et al., 1980) now marketed by Dako, which is routinely used with biopsy samples to diagnose HPV infection. The results obtained are shown in Fig. 6 , and demonstrate a number of interesting points. First, the BPV antiserum (Fig.  6d) had no reactivity against any of the L2-fl-galactosidase fusion proteins (lanes 1 and 5), confirming that the L2 protein is not conserved between different papillomaviruses, and is thus an ideal target for immunological typing of an HPV infection. Second, although the anti-BPV serum reacted very strongly against the HPV-6 Ll-fl-galactosidase fusion protein (lane 6), very little activity was observed against the HPV-16 L 1-fl-galactosidase fusion proteins (lanes 2 to 4). This result indicates that this antiserum was not really effective against HPV-16, and would not be an efficient or reliable reagent for diagnosing HPV-16 infection even where capsid proteins were being produced. Finally, it is apparent that the anti-BPV sera reacted against only the pHX-2 fusion protein (lane 4) and not pHX-1 (lane 3). This indicates that most of the crossreactive epitopes which exist on the L1 protein are contained primarily within the carboxyterminal half of the ORF.
D I S C U S S I O N
Here we have described the expression of the capsid proteins of HPV-6 and HPV-16 in E. co~i, and the production of antisera specific for the HPV-6 L1 and L2 proteins and the HPV-16 L1 protein. These reagents should prove invaluable for early diagnosis of HPV-16 infection in 3088 L. BANKS AND OTHERS samples where this protein is being expressed. These antibodies should also permit detailed analysis of HPV capsid antigen expression in a variety of different cell systems. Western blot analysis Of these proteins has revealed a number of interesting points. Although polyclonal antibodies raised against detergent-disrupted BPV-1 detect papillomavirus genusspecific antigens shared by all papillomaviruses (Orth et al., 1978; Jenson et al., 1980) it is clear that this cross-reactivity varies to a considerable extent. Here it is apparent that antiserum raised to detergent-disrupted BPV-1 reacts very well against HPV-6 L1 protein, but very poorly against HPV-16. Hence the efficacy of using such antiserum for detection of HPV-16 antigens must be questionable. It is notable that the small reactivity observed with the anti-BPV-1 serum is against the carboxy-terminal half of the L1 protein. This is significant from the point of possible vaccine development, since sequences from the carboxy-terminal half of the L1 protein are quite highly conserved between HPV types. Because of the weakness of this reaction with HPV-16 L1, studies on genital dysplasias with anti-BPV serum could give rise to misleading results. Samples that contain HPV-16 L1 may be recorded as negative, whereas those recorded as positive are most likely to contain the relatively harmless HPV-6. The discrimination between HPV-6 and HPV-16 is extremely important in view of the very different prognoses of the two types of lesion. Numerous studies have shown that HPV-6 is associated with rather benign lesions, whereas HPV-16 is associated with malignant carcinomas and advanced premalignant lesions. The failure to detect HPV-16 could therefore be serious.
It is also apparent from the above experiments that the BPV-1 antiserum is highly specific for L1 proteins of the viral capsid, and not L2, confirming that the L2 protein is type-specific as shown previously (Komly et al., 1986) . Interestingly, this protein appears to be very immunogenic since antibodies raised to the HPV-6 L2-~-galactosidase fusion protein are predominantly directed against the L2 portion of the fusion protein. Again this appears particularly significant for possible vaccine development.
The antibodies described here are currently being used to analyse HPV proteins expressed in a variety of lesions. The HPV-6 Ll-/~-galactosidase fusion protein antibodies react with a protein of approximately 60K mol.wt, in Western blots of plantar warts (data not shown) and some reactivity has been observed with anti-HPV-16 LI peptide antibodies on thin sections of cervical biopsies. However, high background reactions have been observed in some cases, and for these reasons the reagents are being refined by the generation of monoclonal antibodies. Ultimately, these reagents should offer the best means of typing a given HPV infection. Also, the fusion proteins described here can also be used to screen sera from cervical cancer patients to determine whether they produce anti-HPV antibodies, and these studies are currently in progress.
